• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Navidea names two appointments to its board of directors

October 14, 2021 By Sean Whooley

Navidea BiopharmaceuticalsNavidea Biopharmaceuticals (NYSE:NAVB) announced today that it appointed two new members to its board of directors.

Thomas Forest Farb-Horch and Agnieszka Winkler joined Dublin, Ohio-based Navidea’s board, effective Oct. 7, each with a three-year term ending concurrently with the company’s 2024 annual stockholders meeting.

According to a news release, Farb-Horch, a veteran of over three decades as an investor and senior executive in the life science and information technology sectors, has served as CEO, president, co-founder and director of Thrive Bioscience. Farb-Horch held other executive positions at Interneuron Pharmaceuticals, Indevus Pharmaceuticals and Cytyc.

Winkler serves on the board of directors of Virco and the board of trustees at both Santa Clara University and the African Diaspora Network. She’s previously served on the board at public companies across multiple disciplines, including SuperCuts, Reno Air, The Cheesecake Factory and Inter-Tel. Winkler was also the founder, chair and CEO of TeamToolz and Winkler Advertising, both of which were acquired.

Navidea’s board has undergone a recent personnel shift, as less than a month after its chair of the board and director S. Kathryn Rouan, along with director Claudine Bruck, retired from those positions. The board appointed Alexander L. Cappello and John K. Scott, Jr., both existing members of the board, as the chair and vice chair of the board, respectively.

“Navidea is pleased to add two highly respected and exceptionally talented individuals to its board of directors,” Navidea CEO Jed Latkin said in the release. “Their combined experience will help guide the company through its next phases of growth and development.”

Navidea develops precision immunodiagnostic agents and immunotherapeutics, including dextran-based drug delivery vehicles that deliver potent drugs to the cells where the virus is multiplying, targeting specific macrophages that replicate.

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Immunotherapy, Personnel, Pharmaceuticals Tagged With: Navidea Biopharmaceuticals, Personnel, Personnel Moves

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS